Neuren Pharmaceuticals' Partner Upgrades Trofinetide Sales Guidance, Implying Royalties of up to $56 Million, Jefferies Says

MT Newswires Live

Aug 06

Neuren Pharmaceuticals' (ASX:NEU) partner Acadia upgraded its fiscal 2026 guidance for trofinetide net product sales to between $480 million and $510 million from a range of $460 million to $490 million, implying royalties of $53 million to $56 million for the company, Jefferies said in a Wednesday note.

The upgrade was due to a strong uptake of Daybue Stix, with Acadia noting that the number of patients returning to Daybue hit a record level during the second quarter.

Second quarter trofinetide royalties for the company were above Jefferies forecasts at roughly AU$18.2 million, up 23% on last year.

Jefferies reaffirmed its buy rating on Neuren Pharmaceuticals and lifted its price target to AU$29.40 from AU$28.80.

Neuren Pharmaceuticals shares rose 2% in morning trade Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2657508098"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2657508098\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2657508098?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657508098","market":"sh","top_or_hot":-1,"title":"Neuren Pharmaceuticals' Partner Upgrades Trofinetide Sales Guidance, Implying Royalties of up to $56 Million, Jefferies Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a>' (ASX:NEU) partner Acadia upgraded its fiscal 2026 guidance for trofinetide net product sales to between $480 million and $510 million from a range of $460 million to $490 million, implying royalties of $53 million to $56 million for the company, Jefferies said in a Wednesday note.</p><p>The upgrade was due to a strong uptake of Daybue Stix, with Acadia noting that the number of patients returning to Daybue hit a record level during the second quarter.</p><p>Second quarter trofinetide royalties for the company were above Jefferies forecasts at roughly AU$18.2 million, up 23% on last year.</p><p>Jefferies reaffirmed its buy rating on Neuren Pharmaceuticals and lifted its price target to AU$29.40 from AU$28.80.</p><p>Neuren Pharmaceuticals shares rose 2% in morning trade Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren Pharmaceuticals' Partner Upgrades Trofinetide Sales Guidance, Implying Royalties of up to $56 Million, Jefferies Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren Pharmaceuticals' Partner Upgrades Trofinetide Sales Guidance, Implying Royalties of up to $56 Million, Jefferies Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-06 09:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a>' (ASX:NEU) partner Acadia upgraded its fiscal 2026 guidance for trofinetide net product sales to between $480 million and $510 million from a range of $460 million to $490 million, implying royalties of $53 million to $56 million for the company, Jefferies said in a Wednesday note.</p><p>The upgrade was due to a strong uptake of Daybue Stix, with Acadia noting that the number of patients returning to Daybue hit a record level during the second quarter.</p><p>Second quarter trofinetide royalties for the company were above Jefferies forecasts at roughly AU$18.2 million, up 23% on last year.</p><p>Jefferies reaffirmed its buy rating on Neuren Pharmaceuticals and lifted its price target to AU$29.40 from AU$28.80.</p><p>Neuren Pharmaceuticals shares rose 2% in morning trade Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2657508098","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657508098","pubTimestamp":1785981135,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neuren Pharmaceuticals'  partner Acadia upgraded its fiscal 2026 guidance for trofinetide net product sales to between $480 million and $510 million from a range of $460 million to $490 million, implying royalties of $53 million to $56 million for the company, Jefferies said in a Wednesday note.The upgrade was due to a strong uptake of Daybue Stix, with Acadia noting that the number of patients returning to Daybue hit a record level during the second quarter.Second quarter trofinetide royalties for the company were above Jefferies forecasts at roughly AU$18.2 million, up 23% on last year.Jefferies reaffirmed its buy rating on Neuren Pharmaceuticals and lifted its price target to AU$29.40 from AU$28.80.Neuren Pharmaceuticals shares rose 2% in morning trade Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","BK7508":"医药生物股","NEU.AU":"NEUREN PHARMACEUTICALS LTD"},"translate_title":"Jefferies 表示，Neuren Pharmaceuticals 的合作伙伴升级了 Trofinetide 销售指导，这意味着特许权使用费高达 5600 万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":1},"content_text":"Neuren Pharmaceuticals' (ASX:NEU) partner Acadia upgraded its fiscal 2026 guidance for trofinetide net product sales to between $480 million and $510 million from a range of $460 million to $490 million, implying royalties of $53 million to $56 million for the company, Jefferies said in a Wednesday note.The upgrade was due to a strong uptake of Daybue Stix, with Acadia noting that the number of patients returning to Daybue hit a record level during the second quarter.Second quarter trofinetide royalties for the company were above Jefferies forecasts at roughly AU$18.2 million, up 23% on last year.Jefferies reaffirmed its buy rating on Neuren Pharmaceuticals and lifted its price target to AU$29.40 from AU$28.80.Neuren Pharmaceuticals shares rose 2% in morning trade Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}